← Leaderboards
Mary Olanich
Leidos Biomedical Research, Inc.
$1,304,455
Attributed
$1,304,455
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $500K · FY2018–23$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,304,455 · 1
By mechanism
N01$1,304,455 · 1
Top collaborators
No co-investigators on record.
Most similar at Leidos Biomedical Research, Inc.
Same institution · by research overlap
- David Heimbrook$2,362,140,846
- Leonard Freedman$1,216,107,431
- Lynn Briscoe$495,968,635
- Ralph Parchment$197,348,011
- Ethan Dmitrovsky$597,515,186
Others in their field
Other Emerging Leaders on “Biomarker Evaluation”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$61,895,626
- Yunda Huang · Fred Hutchinson Cancer Center$53,780,853
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
Research focus
Biomarker EvaluationDivision Of Cancer Epidemiology And GeneticsSlideStainsCervicalCervical Cancer ScreeningCohortCytologyData FilesDiagnosticDigitalDigital ImagingEnrollmentEvaluationHuman PapillomavirusImaging DetectionManualsMinorPap SmearPublic Health RelevanceScanningScreeningWomanArchives
Grant awards (4)
NCI-DCEG; Automated evaluation of biomarker-stained slides;$25,616
N01 · FY2023 · CA · contact PI
NCI-DCEG; Automated evaluation of biomarker-stained slides;$434,049
N01 · FY2021 · CA · contact PI
NCI-DCEG; Appropriated; Automated evaluation of biomarker-stained slides; 09/24/2018-09/23/2023$344,790
N01 · FY2019 · CA · contact PI
HHSN261201500003I; HHSN26100070; 400.020.0070.0001; NCI-DCEG; Appropriated; Automated evaluation of biomarker-stained slides; 09/24/2018-09/23/2023$500,000
N01 · FY2018 · CA · contact PI